Ranibizumab biosimilar(Sun Pharmaceutical Industries)

N/A

Report date: 2025/03/07 17:34:44

Base Information

Drug NameRanibizumab biosimilar(Sun Pharmaceutical Industries)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionAngiogenesis inhibitorsVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSun Pharmaceutical Industries Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSun Pharmaceutical Industries Ltd
Inactive CompaniesN/A
Active IndicationsMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A